Merck Says KEYTRUDA Plus Trastuzumab And Chemotherapy Significantly Improved Progression-Free Survival Vs. Trastuzumab And Chemotherapy In First-Line HER2-Positive Advanced Gastric Or Gastroesophageal Junction (GEJ) Adenocarcinom
Portfolio Pulse from Benzinga Newsdesk
Merck has announced that its drug KEYTRUDA, in combination with trastuzumab and chemotherapy, has significantly improved progression-free survival in first-line HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma patients, compared to trastuzumab and chemotherapy alone.
October 20, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA has shown significant improvement in treating advanced gastric cancer patients, which could potentially boost the company's revenues and market position in the oncology sector.
The positive results from the KEYTRUDA trial could lead to increased sales for Merck, as it may become a preferred treatment option for advanced gastric cancer. This could potentially increase Merck's revenues and strengthen its position in the oncology market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100